These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 30008435)

  • 1. Targeted overexpression of catalase to mitochondria does not prevent cardioskeletal myopathy in Barth syndrome.
    Johnson JM; Ferrara PJ; Verkerke ARP; Coleman CB; Wentzler EJ; Neufer PD; Kew KA; de Castro Brás LE; Funai K
    J Mol Cell Cardiol; 2018 Aug; 121():94-102. PubMed ID: 30008435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiolipin Remodeling Defects Impair Mitochondrial Architecture and Function in a Murine Model of Barth Syndrome Cardiomyopathy.
    Zhu S; Chen Z; Zhu M; Shen Y; Leon LJ; Chi L; Spinozzi S; Tan C; Gu Y; Nguyen A; Zhou Y; Feng W; Vaz FM; Wang X; Gustafsson AB; Evans SM; Kunfu O; Fang X
    Circ Heart Fail; 2021 Jun; 14(6):e008289. PubMed ID: 34129362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barth syndrome-related cardiomyopathy is associated with a reduction in myocardial glucose oxidation.
    Greenwell AA; Gopal K; Altamimi TR; Saed CT; Wang F; Tabatabaei Dakhili SA; Ho KL; Zhang L; Eaton F; Kruger J; Al Batran R; Lopaschuk GD; Oudit GY; Ussher JR
    Am J Physiol Heart Circ Physiol; 2021 Jun; 320(6):H2255-H2269. PubMed ID: 33929899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a transgenic short hairpin RNA-induced murine model of Tafazzin deficiency.
    Soustek MS; Falk DJ; Mah CS; Toth MJ; Schlame M; Lewin AS; Byrne BJ
    Hum Gene Ther; 2011 Jul; 22(7):865-71. PubMed ID: 21091282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiolipin deficiency in Barth syndrome is not associated with increased superoxide/H
    Goncalves RLS; Schlame M; Bartelt A; Brand MD; Hotamışlıgil GS
    FEBS Lett; 2021 Feb; 595(3):415-432. PubMed ID: 33112430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of Mitochondrial Ca
    Bertero E; Nickel A; Kohlhaas M; Hohl M; Sequeira V; Brune C; Schwemmlein J; Abeßer M; Schuh K; Kutschka I; Carlein C; Münker K; Atighetchi S; Müller A; Kazakov A; Kappl R; von der Malsburg K; van der Laan M; Schiuma AF; Böhm M; Laufs U; Hoth M; Rehling P; Kuhn M; Dudek J; von der Malsburg A; Prates Roma L; Maack C
    Circulation; 2021 Nov; 144(21):1694-1713. PubMed ID: 34648376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tafazzin deficiency impairs CoA-dependent oxidative metabolism in cardiac mitochondria.
    Le CH; Benage LG; Specht KS; Li Puma LC; Mulligan CM; Heuberger AL; Prenni JE; Claypool SM; Chatfield KC; Sparagna GC; Chicco AJ
    J Biol Chem; 2020 Aug; 295(35):12485-12497. PubMed ID: 32665401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endurance training ameliorates complex 3 deficiency in a mouse model of Barth syndrome.
    Soustek MS; Baligand C; Falk DJ; Walter GA; Lewin AS; Byrne BJ
    J Inherit Metab Dis; 2015 Sep; 38(5):915-22. PubMed ID: 25860817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barth Syndrome Cardiomyopathy: An Update.
    Pang J; Bao Y; Mitchell-Silbaugh K; Veevers J; Fang X
    Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Barth Syndrome Patient-Derived
    Snider PL; Sierra Potchanant EA; Sun Z; Edwards DM; Chan KK; Matias C; Awata J; Sheth A; Pride PM; Payne RM; Rubart M; Brault JJ; Chin MT; Nalepa G; Conway SJ
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AAV-Mediated TAZ Gene Replacement Restores Mitochondrial and Cardioskeletal Function in Barth Syndrome.
    Suzuki-Hatano S; Saha M; Rizzo SA; Witko RL; Gosiker BJ; Ramanathan M; Soustek MS; Jones MD; Kang PB; Byrne BJ; Cade WT; Pacak CA
    Hum Gene Ther; 2019 Feb; 30(2):139-154. PubMed ID: 30070157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome.
    Huang Y; Powers C; Moore V; Schafer C; Ren M; Phoon CK; James JF; Glukhov AV; Javadov S; Vaz FM; Jefferies JL; Strauss AW; Khuchua Z
    Orphanet J Rare Dis; 2017 Mar; 12(1):49. PubMed ID: 28279226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide.
    Sabbah HN
    Heart Fail Rev; 2021 Mar; 26(2):237-253. PubMed ID: 33001359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barth syndrome.
    Jefferies JL
    Am J Med Genet C Semin Med Genet; 2013 Aug; 163C(3):198-205. PubMed ID: 23843353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Reactive Oxygen Species-Mediated Ca
    Liu X; Wang S; Guo X; Li Y; Ogurlu R; Lu F; Prondzynski M; de la Serna Buzon S; Ma Q; Zhang D; Wang G; Cotton J; Guo Y; Xiao L; Milan DJ; Xu Y; Schlame M; Bezzerides VJ; Pu WT
    Circulation; 2021 May; 143(19):1894-1911. PubMed ID: 33793303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A critical appraisal of the tafazzin knockdown mouse model of Barth syndrome: what have we learned about pathogenesis and potential treatments?
    Ren M; Miller PC; Schlame M; Phoon CKL
    Am J Physiol Heart Circ Physiol; 2019 Dec; 317(6):H1183-H1193. PubMed ID: 31603701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies.
    Wang G; McCain ML; Yang L; He A; Pasqualini FS; Agarwal A; Yuan H; Jiang D; Zhang D; Zangi L; Geva J; Roberts AE; Ma Q; Ding J; Chen J; Wang DZ; Li K; Wang J; Wanders RJ; Kulik W; Vaz FM; Laflamme MA; Murry CE; Chien KR; Kelley RI; Church GM; Parker KK; Pu WT
    Nat Med; 2014 Jun; 20(6):616-23. PubMed ID: 24813252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice.
    Russo S; De Rasmo D; Signorile A; Corcelli A; Lobasso S
    Sci Rep; 2022 Nov; 12(1):19847. PubMed ID: 36400945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of tafazzin results in decreased myoblast differentiation in C2C12 cells: A myoblast model of Barth syndrome and cardiolipin deficiency.
    Lou W; Reynolds CA; Li Y; Liu J; Hüttemann M; Schlame M; Stevenson D; Strathdee D; Greenberg ML
    Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Aug; 1863(8):857-865. PubMed ID: 29694924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel mitochondrial localization signals in human Tafazzin, the cause of the inherited cardiomyopathic disorder Barth syndrome.
    Dinca AA; Chien WM; Chin MT
    J Mol Cell Cardiol; 2018 Jan; 114():83-92. PubMed ID: 29129703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.